GlassScriptPhysician profile
Susan S Westerlund
NPI 1508804832
$4,640.28
in general payments reported to CMS, 2019-2025
51 companies · $19.17 in 2025
The $19.17 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $1,165 · 2021: $920 · 2022: $713 · 2023: $476 · 2024: $99.46 · 2025: $19.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $686.65 | 2019-2023 | Wegovy |
| Abbvie INC. | $374.82 | 2019-2022 | |
| Amgen INC. | $349.78 | 2019-2023 | Prolia, Evenity, Repatha |
| Astellas Pharma US INC | $292.89 | 2019-2023 | Veozah, Myrbetriq |
| Radius Health, INC. | $243.55 | 2019-2024 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.06 | 2019-2023 | Ofev |
| Myriad Women'S Health, INC. | $160.28 | 2023 | Myrisk |
| Glaxosmithkline, LLC. | $157.93 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $142.54 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.58 | 2019-2023 | Trintellix |
| Eisai INC. | $132.88 | 2021 | |
| Amag Pharmaceuticals, INC. | $125.40 | 2019 | |
| Lupin INC. | $122.38 | 2019-2020 | |
| Amarin Pharma, INC. | $118.07 | 2020-2021 | |
| Lilly USA, LLC | $108.94 | 2019-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Westerlund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.